INCY: Summary for Incyte Corporation - Yahoo! Singapore Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:09pm SGT - The Singapore stock market is closed.

To create a watchlist or portfolio of shares, Register

FINANCE HOME PAGE

INVESTING

FINANCE NEWS

Incyte Corporation (INCY)

At 5:00AM SGT: 10.28 USD 0.00 (0.00%)

MORE ON INCY

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Incyte Corporation (NGM:INCY) Delayed quote data

Last Trade:	10.28 USD
Trade Time:	5:00AM SGT
Change:	0.00 (0.00%)
Prev Close:	10.28
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	12.25

Day's Range:	N/A - N/A
52wk Range:	1.96 - 11.24
Volume:	0
Avg Vol (3m):	3,302,710
Market Cap:	1.22B
P/E (ttm):	N/A
EPS (ttm):	-1.76
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Use Y! Toolbar to track stocks

Add INCY to Portfolio

Download Data

HEADLINES

•	Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
	Business Wire (Wed 5:10am)

•	Nektar adds to board of directors
	at bizjournals.com (Wed, Feb 3)

•	Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011
	Business Wire (Fri, Jan 29)

•	Eli Lilly Misses by a Penny
	Zacks.com (Thu, Jan 28)

•	Another Deal for Novartis
	Zacks.com (Thu, Jan 21)

•	Incyte to Present at the 28th Annual JPMorgan Healthcare Conference
	Business Wire (Wed, Jan 6)

•	Analysts Name Top Biotech Stocks for 2010: BioBuzz
	at TheStreet.com (Tue, Jan 5)

•	Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
	at Seeking Alpha (Thu, Dec 24)

•	Pharma Spreads Holiday Cheer in Bevy of Biotech Deals
	at Seeking Alpha (Thu, Dec 24)

•	Lightning Round OT: Kinder Morgan Energy, Incyte and More
	at CNBC (Thu, Dec 24)

•	Another Deal for Incyte
	Zacks.com (Wed, Dec 23)

•	Some Incyte Into Why These Drugs Rock
	at Motley Fool (Wed, Dec 23)

•	Deal activity lifts US stocks
	at FT.com (Tue, Dec 22)

•	INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
	EDGAR Online (Tue, Dec 22)

•	Pharma's Holiday Shopping Spree
	at CNBC (Tue, Dec 22)

•	Incyte shares rise on Eli Lilly deal
	AP (Tue, Dec 22)

•	A Slew of New Deals Move Pharma Stocks
	Indie Research (Mon, Dec 21)

More Headlines for INCY...

ANALYST

EPS Est (next year) (Dec-09) :	-1.61
EPS Est (in 2 years) (Dec-10) :	-1.31
Avg Rec (current)*:	1.5
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.

Full Company Profile

Add to Portfolio

Email to a Friend

•